Please login to the form below

ledipasvir

This page shows the latest ledipasvir news and features for those working in and with pharma, biotech and healthcare.

Gilead wins European approval for triple hep C combination Vosevi

The EC also approved an extension for Harvoni (ledipasvir/sofobuvir), - which was previously authorised to treat adults with chronic HCV genotypes 1, 3, 4, 5, or 6 - and will now include

Latest news

Merck & Co pulls out of hepatitis C R&D as market shrinks

In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half
Gilead makes $11.9bn play for CAR-T specialist Kite

Gilead's deal comes as it faces a sharp slowdown in sales of its HCV therapies - led by Harvoni (sofosbuvir and ledipasvir) and Sovaldi (sofosbuvir) - which has led investors to call
Gilead gets OK for three-in-one hep C therapy in US

Other NS5A inhibitors on the market for HCV include Gilead's ledipasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and Merck &Co's elbasvir.
Samsung Bioepis wins CHMP nod for second Humira biosimilar

Both were reviewed under the accelerated assessment protocol because despite the robust efficacy of current drugs such as Gilead's Harvoni (sofosbuvir/ledipasvir) and AbbVie's Viekira (ombitasvir/paritaprevir/ritonavir and
Two new hepatitis C therapies fast-tracked in Europe

Sofosbuvir and velpatasvir are the two active ingredients in Gilead's recently-approved two-drug HCV combination Epclusa, as a successor to its massively successful Harvoni (sofosbuvir/ledipasvir) but with activity

More from news
Approximately 4 fully matching, plus 62 partially matching documents found.

Latest Intelligence

AbbVie: New firm, new thinking

Gilead Sciences has emerged as the leader in this field with Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), both of which have already made billions of dollars.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Account Manager – Healthcare Advertising: Salary TBC

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Sudler London - Account Director: Competitive

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Sudler London - Senior Medical Writer: Competitive

Medical Writer - Creative and Scientific Projects: DOE

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Manager: Negotiable

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Healthcare PR Senior Account Manager: Salary TBC

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Account Manager- 4 days per week or full-time: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Training Manager - Surrey: Competitive Salary &Bonus

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Graduate Scientific Editor: DOE

Associate Scientific Director: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....